Grifols (GIFLF) Receivables - Net (2009 - 2025)
Grifols' (GIFLF) quarterly Receivables - Net came in at $757.8 million in Q4 2025, up 0.59% on a YoY basis from $753.4 million in Q4 2024, and up 0.59% quarter-over-quarter from $753.4 million in Q4 2024.
Analysis
Grifols (GIFLF) Receivables - Net (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Receivables - Net for 17 consecutive years, with $757.8 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 0.59% year-over-year to $757.8 million; the trailing twelve-month figure through Dec 2025 stood at $757.8 million (up 0.59% YoY), and the FY2025 full-year result was $735.5 million, down 7.17% from the prior year.
- Receivables - Net rose to $757.8 million in Q4 2025 per GIFLF's latest filing, from $753.4 million in the prior quarter.
- Across five years, Receivables - Net topped out at $757.8 million in Q4 2025 and bottomed at -$26.9 million in Q4 2023.
- Historically, Receivables - Net has averaged $520.5 million across 5 years, with a median of $621.4 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Receivables - Net plunged 104.33% in 2023, then surged 2900.75% in 2024.
- Over 5 years, Receivables - Net stood at $496.6 million in 2021, then gained by 25.12% to $621.4 million in 2022, then slumped by 104.33% to -$26.9 million in 2023, then soared by 2900.75% to $753.4 million in 2024, then rose by 0.59% to $757.8 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods registered $757.8 million, $753.4 million, and -$26.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 757.79 Mn |
| Dec 31, 2024 | 753.36 Mn |
| Dec 31, 2023 | -26.90 Mn |
| Dec 31, 2022 | 621.41 Mn |
| Dec 31, 2021 | 496.64 Mn |
| Dec 31, 2020 | 456.92 Mn |
| Sep 30, 2020 | 663.81 Mn |
| Mar 31, 2020 | 560.38 Mn |
| Dec 31, 2019 | 409.32 Mn |
| Sep 30, 2019 | 516.62 Mn |
| Mar 31, 2019 | 678.24 Mn |
| Dec 31, 2018 | 307.23 Mn |
| Sep 30, 2018 | 538.34 Mn |
| Jun 30, 2018 | 366.66 Mn |
| Mar 31, 2018 | 496.64 Mn |
| Dec 31, 2017 | 336.98 Mn |
| Jun 30, 2017 | 363.19 Mn |
| Dec 31, 2016 | 446.63 Mn |
| Sep 30, 2016 | 425.36 Mn |
| Jun 30, 2016 | 491.01 Mn |